Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is April 17, 2026, covering a share repurchase executed on April 16, 2026. The transaction was conducted through BNP Paribas SA as part of an existing non-discretionary buyback programme announced on February 17, 2026.
Key Financial Metrics and Transaction Details
- Shares Purchased: 330,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,116.00 GBp; highest price paid was 2,136.00 GBp.
- Average Price: Volume-weighted average price paid was 2,125.06 GBp.
- Treasury Holdings: Following this purchase, GSK holds 259,417,615 ordinary shares in treasury.
- Shares in Issue: 4,056,773,154 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 6.39% of total voting rights.
- Cumulative Programme Activity: Since February 17, 2026, the company has purchased 19,526,521 ordinary shares.
Material Changes
The filing details a reduction in the number of shares in issue due to the acquisition of treasury stock. There are no reported changes to revenue, profit, cash flow, debt, or liquidity metrics in this specific filing, as it is a disclosure of a capital transaction rather than a financial results report.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025. The transaction was executed across multiple trading venues (BATE, CHIX, XLON) in compliance with market rules.
Investor Verification Checklist
- Verify the total cost of the buyback programme against the company's available cash reserves and debt covenants.
- Confirm the remaining authorization limit for the buyback programme announced on February 17, 2026.
- Review the impact of the 6.39% treasury holding on earnings per share (EPS) calculations.
- Check the "Risk Factors" in the 2025 Form 20-F for context on the forward-looking statement disclaimer.